Spots Global Cancer Trial Database for Camrelizumab and Chemotherapy Combined With Endoscopic Surgery for Recurrent Nasopharyngeal Carcinoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Camrelizumab and Chemotherapy Combined With Endoscopic Surgery for Recurrent Nasopharyngeal Carcinoma
Official Title: A Prospective, Single-arm, Multi-center Clinical Study of Camrelizumab and Chemotherapy Combined With Endoscopic Surgery in the Treatment of Recurrent Nasopharyngeal Carcinoma
Study ID: NCT05011227
Conditions
Study Description
Brief Summary: To explore the effect of Camrelizumab and chemotherapy combining with endoscopic surgery in the treatment of recurrent nasopharyngeal carcinoma.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Fujian Medical University Union Hospital, Fuzhou, Fujian, China
Fujian Provincial Hospital, Fuzhou, Fujian, China
Shenzhen Second People's Hospital, Shenzhen, Guangdong, China
The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, Guangxi, China
The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China
Eye& ENT Hospital, Fudan University, Shanghai, Shanghai, China
Shanghai Zhongshan Hospital,Fudan University, Shanghai, Shanghai, China
Contact Details
Name: Hongmeng Yu, MD,PHD
Affiliation: Eye&ENT Hospital,Fudan University
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
